PALI
ACHAT TOTAL: 125000 titres (~250182 USD) VENTE TOTALE: 198678 titres (~409879 USD)
- Insiders
- Baltera Robert Jr., Finley John David, Jones Mitchell Lawrence
- Total bought
- $250,182
- Total sold
- $409,879
- Last activity
- 2026-07-09
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-03
PALI presents a speculative event-driven setup anchored by a genuine FDA IND clearance for PALI-2108 and bullish sell-side initiation, but the fundamental backdrop is critically weak — zero revenue, persistent cash…
The first sentence of the analysis written for PALI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | -4914.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | -4912.4% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -5228.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -4926.4% | 0.0% | 0.0% | |
| Current Ratio | 28.952 | 3.243 | 5.154 | 4.891 | 4.610 | |
| Quick Ratio | 28.952 | 3.243 | 5.154 | 4.891 | 4.610 | |
| Solvency Ratio | -3.380 | -4.261 | -4.489 | -4.341 | -5.171 | |
| Cash Ratio | 28.772 | 3.035 | 4.807 | 4.111 | 4.205 | |
| Price To Earnings Ratio | -7.833 | -0.162 | -0.328 | -4.719 | -0.455 | |
| Price To Earnings Growth Ratio | 0.081 | 0.003 | -0.005 | 0.048 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.081 | 0.003 | -0.005 | 0.048 | -0.000 | |
| Price To Earnings Diluted Ratio | -7.833 | -0.162 | -0.328 | -4.719 | -0.383 | |
| Price To Earnings Diluted Growth Ratio | 0.081 | 0.003 | -0.005 | 0.047 | -0.000 | |
| Price To Book Ratio | 1.011 | 0.312 | 0.357 | 5.501 | 1.643 | |
| Price To Sales Ratio | 0.000 | 0.000 | 16.143 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -12.061 | -0.192 | -0.362 | -5.134 | -0.819 | |
| Price To Operating Cash Flow Ratio | -12.061 | -0.192 | -0.363 | -5.138 | -0.819 | |
| Debt To Assets Ratio | 0.001 | 0.016 | 0.026 | 0.026 | 0.016 | |
| Debt To Equity Ratio | 0.001 | 0.023 | 0.033 | 0.032 | 0.027 | |
| Debt To Capital Ratio | 0.001 | 0.022 | 0.032 | 0.031 | 0.026 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.038 | 1.452 | 1.242 | 1.263 | 1.699 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.022 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.340 | -3.768 | -4.305 | -4.436 | -5.919 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -44.532 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | -207.012 | -158.495 | -70.988 | -141.030 | -9.745 | |
| Interest Coverage Ratio | -1,805.600 | -1,238.250 | -871.333 | -1,209.308 | -17.454 | |
| Short Term Operating Cash Flow Coverage Ratio | -152.775 | -154.342 | -70.462 | -151.818 | -169.805 | |
| Operating Cash Flow Coverage Ratio | -152.775 | -72.148 | -30.171 | -33.069 | -74.236 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -2,783.250 | -1,336.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -2,783.250 | -1,336.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.148 | 0.507 | 0.654 | -3.978 | -0.075 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-20.0% |
| Ebit Margin | 0.0% | 0.0% | ▲982.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲982.5% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1045.6% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Net Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲985.3% |
| Current Ratio | 28.952 | ▲25.709 | ▲19.582 |
| Quick Ratio | 28.952 | ▲25.709 | ▲19.582 |
| Solvency Ratio | -3.380 | ▲0.881 | ▲0.948 |
| Cash Ratio | 28.772 | ▲25.737 | ▲19.786 |
| Price To Earnings Ratio | -7.833 | ▼-7.671 | ▼-5.134 |
| Price To Earnings Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Forward Price To Earnings Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Price To Earnings Diluted Ratio | -7.833 | ▼-7.671 | ▼-5.148 |
| Price To Earnings Diluted Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Price To Book Ratio | 1.011 | ▲0.699 | ▼-0.754 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-3.229 |
| Price To Free Cash Flow Ratio | -12.061 | ▼-11.869 | ▼-8.347 |
| Price To Operating Cash Flow Ratio | -12.061 | ▼-11.869 | ▼-8.346 |
| Debt To Assets Ratio | 0.001 | ▼-0.015 | ▼-0.016 |
| Debt To Equity Ratio | 0.001 | ▼-0.022 | ▼-0.022 |
| Debt To Capital Ratio | 0.001 | ▼-0.021 | ▼-0.022 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.038 | ▼-0.414 | ▼-0.301 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.004 |
| Operating Cash Flow Ratio | -2.340 | ▲1.428 | ▲1.814 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲8.906 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.000 |
| Debt Service Coverage Ratio | -207.012 | ▼-48.518 | ▼-89.558 |
| Interest Coverage Ratio | -1805.600 | ▼-567.350 | ▼-777.211 |
| Short Term Operating Cash Flow Coverage Ratio | -152.775 | ▲1.567 | ▼-12.934 |
| Operating Cash Flow Coverage Ratio | -152.775 | ▼-80.627 | ▼-80.295 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲823.850 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲823.850 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.148 | ▼-0.359 | ▲0.697 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $130.8M | $2.3M | $4.0M | $68.6M | $12.1M | |
| Enterprise value | -$2.5M | -$7.3M | -$8.0M | $56.7M | $1.8M | |
| EV / Sales | 0.00x | 0.00x | -32.11x | 0.00x | 0.00x | |
| EV / Op. cash flow | 0.23x | 0.60x | 0.72x | -4.24x | -0.12x | |
| EV / Free cash flow | 0.23x | 0.60x | 0.72x | -4.24x | -0.12x | |
| EV / EBITDA | 0.15x | 0.51x | 0.65x | -3.98x | -0.07x | |
| Net debt / EBITDA | 7.95x | 0.67x | 0.98x | 0.84x | 0.42x | |
| Current ratio | 28.95x | 3.24x | 5.15x | 4.89x | 4.61x | |
| Income quality | 0.65x | 0.84x | 0.91x | 0.94x | 0.56x | |
| Graham net-net | $2 | $5 | $21 | $12 | $440 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.1% | 100.1% | 100.1% | 100.1% | 109.9% | |
| Working capital | $129.6M | $7.3M | $10.7M | $11.7M | $9.0M | |
| Invested capital | $129.6M | $7.3M | $10.9M | $12.0M | $9.1M | |
| Return on assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | |
| Operating ROA | -24.9% | -119.2% | -87.7% | -111.2% | -539.0% | |
| Return on tangible assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | |
| Return on equity | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% | |
| Return on invested capital | -13.9% | -190.2% | -111.3% | -121.5% | -409.7% | |
| Return on capital employed | -13.9% | -194.4% | -114.0% | -123.3% | -417.9% | |
| Earnings yield | -12.8% | -618.0% | -304.8% | -20.8% | -219.9% | |
| Free cash flow yield | -8.3% | -521.9% | -276.0% | -19.5% | -122.1% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.0% | -0.1% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 100.0% | 333.3% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 1.6% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 2480.8% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 2757.2% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 249.6% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 216d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 216d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 216d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5499.4%EV / Sales n/aEV / EBITDA ▼-70.7%EV / Op. cash flow ▼-0.370Earnings yield ▲+6.051
Profitability
Return on equity ▲+1.797Return on assets ▲+1.202Return on invested capital ▲+1.763Return on capital employed ▲+1.805Operating ROA ▲+0.943Income quality ▼-0.198Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+25.709Net debt / EBITDA ▲+7.281Working capital ▲+122327000.000Invested capital ▲+122240000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+981.0%EV / Sales n/aEV / EBITDA ▲+299.0%EV / Op. cash flow ▲+0.352Earnings yield ▲+2.071
Profitability
Return on equity ▲+3.484Return on assets ▲+2.002Return on invested capital ▲+3.958Return on capital employed ▲+4.040Operating ROA ▲+5.141Income quality ▲+0.091Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+24.342Net debt / EBITDA ▲+7.525Working capital ▲+120575000.000Invested capital ▲+120463000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-23 Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market.
- 2026-07-10 Palisade Bio to Participate in the Leerink Partners Therapeutics Forum Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr.
- 2026-07-10 Palisade Bio to Participate in the Leerink Partners Therapeutics Forum Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company''s clinical development strategy, recent progress advancing PALI-2108 and upcoming milestones across its inflammatory bowel disease programs.
- 2026-07-10 Palisade Bio: A Unique MoA Targeting The UC And Crohn''s Disease Markets Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn''s disease. PALI-2108''s Phase 1 trials showed favorable safety, target engagement, and early clinical activity, supporting a differentiated mechanism of action. PALI''s $132.6 million cash runway funds operations through key Phase 2 efficacy readouts in 2027–2028, reducing near-term dilution risk.
- 2026-06-29 Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe
- 2026-06-11 Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors. “We are pleased to welcome both Robert and Jordan to the Palisade Bio Board of Directors,” said JD Finley, Chief Executive Officer of Palisade Bio.
- 2026-06-09 Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn''s Disease at New York Academy of Sciences Symposium Presentation to highlight fibrostenotic Crohn''s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach
- 2026-05-27 Palisade Bio to Participate in the Jefferies Global Healthcare Conference Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York. The Company''s presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET.
- 2026-05-12 Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.
- 2026-05-12 Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations. Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn''s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications.